900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 103
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 950,41k | S.O. | 1981 |
Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | S.O. | S.O. | 1963 |
Mr. Franco Valle | CFO & Principal Accounting Officer | 673,66k | S.O. | 1981 |
Caroline Perez- Dupont | Senior Vice President of Contracts | S.O. | S.O. | S.O. |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
L’ISS Governance QualityScore de Biomea Fusion, Inc. en date du 1 mai 2024 est 9. Les scores principaux sont Audit : 6; Société : 9; Droits des actionnaires : 8; Compensation : 9.